secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124558
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Q3 net loss $29.9M; ALLOHA heme trial shows no relapses in 16 treatment patients
--------------------------------------------------------------------------------

- Net loss $29.9M in Q3 2024 vs $23.0M in Q3 2023; revenue $1.0M vs $3.9M.
- Cash $271.1M, excluding $5M restricted cash; funding operations into Q4 2026.
- ALLOHA Phase 1 heme trial: 16/16 treatment-arm patients relapse-free and MRD-negative as of July 8 cutoff; 3/11 control-arm relapses.
- On track to dose first patient with multiplex TCR-T therapy and provide Phase 1 update by end of 2024.
- IND filing for MAGE-A4-targeted TCR-T (TSC-202-A0201) planned by end of year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017024124558/0000950170-24-124558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017024124558/tcrx-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer